Notably, dysregulation of the lncRNA-E2F1 axis can be affected by certain signaling pathways, which provide novel insights into drug development for cancer therapy (Logotheti et al., 2020; Xiao et al., 2022). The gene discussed is E2F1; the disease is cancer.